Smoking as a contributing factor for development of polycythemia vera and related neoplasms

Leukemia Research

Volumn 39, Issue 11, 2015, Pages 1137-1145

  Hasselbalch, Hans Carl ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Atherosclerosis; Chronic myelomonocytic stimulation; Essential thrombocythemia; IL 8; JAK STAT signaling; Myeloproliferative neoplasms MPNs; NF B; Polycythemia vera; Primary myelofibrosis; Smoking; Thrombosis

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINE; STAT PROTEIN; TRANSCRIPTION FACTOR NF E2;

ACUTE MYELOBLASTIC LEUKEMIA; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; EPIDEMIOLOGICAL DATA; ERYTHROPOIESIS; HUMAN; IN VIVO STUDY; LEUKOCYTE ACTIVATION; LEUKOCYTOSIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; OXIDATIVE STRESS; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84955353963     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.09.002     Document Type: Review

References (100)

1. P.J. Campbell, A.R. Green, The myeloproliferative disorders, N. Engl. J. Med.355 (2006) 2452-2466.
2. H.C. Hasselbalch, Chronic inflammation as a promotor of mutagenesis inessential thrombocythemia, polycythemia vera and myelofibrosis. A humaninflammation model for cancer development? Leuk Res. 37 (2) (2013) 214-220.
3. H.C. Hasselbalch, Perspectives on chronic inflammation in essentialthrombocythemia, polycythemia vera, and myelofibrosis: is chronicinflammation a trigger and driver of clonal evolution and development ofaccelerated atherosclerosis and second cancer? Blood 119 (2012) 3219-3225.
4. R. Kralovics, F. Passamonti, A.S. Buser, et al., A gain of function mutation ofJAK2 in myeloproliferative disorders, N. Engl. J. Med. 352 (2005) 1779-1790.
5. E.J. Baxter, L.M. Scott, P.J. Campbell, et al., Acquired mutation of the tyrosinekinase JAK2 in human myeloproliferative disorders, Lancet 365 (2005) 1054-1061.
6. R.L. Levine, M. Wadleigh, J. Cools, et al., Activating mutation in the tyrosinekinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloidmetaplasia with myelofibrosis, Cancer Cell 7 (2005) 387-397.
7. R.L. Levine, A. Pardanani, A. Tefferi, D.G. Gilliland, Role of JAK2 in thepathogenesis and therapy of myeloproliferative disorders, Nat. Rev. Cancer 7 (2007) 673-683.
8. W. Vainchenker, F. Delhommeau, S.N. Constantinescu, O.A. Bernard, Newmutations and pathogenesis of myeloproliferative neoplasms, Blood 188 (2011) 1723-1735.
9. T. Klampfl, H. Gisslinger, A.S. Harutyunyan, et al., Somatic mutations ofcalreticulin in myeloproliferative neoplasms, N. Engl. J. Med. 369 (25) (2013) 2379-2390.
10. J. Nangalia, C.E. Massie, E.J. Baxter, et al., Somatic CALR mutations inmyeloproliferative neoplasms with nonmutated JAK2, N. Engl. J. Med. 369 (25) (2013) 2391-2405.
11. M. Cazzola, R. Kralovics, From Janus kinase 2 to calreticulin: the clinicallyrelevant genomic landscape of myeloproliferative neoplasms, Blood 123 (24) (2014) 3714-3719.
12. A.L. Mui, The role of STATs in proliferation, differentiation, and apoptosis, Cell. Mol. Life Sci. 55 (1999) 1547-1558.
13. P.J. Murray, The JAK-STAT signaling pathway: input and output integration, J. Immunol. 178 (2007) 2623-2629.
14. M.M. Seavey, P. Dobrzanski, The many faces of Janus kinase, Biochem.Pharmacol. 83 (2011) 1136-1145.
15. W. Vainchenker, S.N. Constantinescu, JAK/STAT signaling in hematologicalmalignancies, Oncogene 32 (21) (2013) 2601-2613.
16. H. Yu, D. Pardoll, R. Jove, STATs in cancer inflammation and immunity: aleading role for STAT3, Nat. Rev. Cancer 9 (2009) 798-809.
17. H.C. Hasselbalch, The role of cytokines in the initiation and progression ofmyelofibrosis, Cytokine Growth Factor Rev. 24 (2) (2013) 133-145.
18. S. Iho, Y. Tanaka, R. Takauji, et al., Nicotine induces human neutrophils toproduce IL-8 through the generation of peroxynitrite and subsequentactivation of NF-kappaB, J. Leukoc. Biol. 74 (2003) 942-951.
19. G.S. Tell, R.H.J. Grimm, V. r, O.D. Ellar, L. Theodorsen, The relationship ofwhite cell count, platelet count, and hematocrit to cigarette smoking inadolescents: the Oslo Youth Study, Circulation 72 (5) (1985) 971-974.
20. J. Danesh, P. Whincup, M. Walker, et al., Low grade inflammation andcoronary heart disease: prospective study and updated meta-analyses, BMJ321 (2000) 199-204.
21. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens, Plasmaconcentration of C-reactive protein and risk of developing peripheralvascular disease, Circulation 97 (5) (1998) 425-428.
22. G. Brevetti, G. Giugliano, L. Brevetti, W.R. Hiatt, Inflammation in peripheralarterial disease, Circulation 122 (2010) 1862-1875.
23. L. Lu, D.F. Mackay, J.P. Pell, Meta-analysis of the association betweensmoking and peripheral arterial disease, Heart 100 (2014) 414-423.
24. G. Siasos, V. Tsigkou, E. Kokkou, et al., Smoking and atherosclerosis:mechanisms of disease and new therapeutic approaches, Curr. Med. Chem.21 (34) (2014) 3936-3948.
25. G.P. Pfeifer, M.F. Denissenko, M. Olivier, et al., Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers, Oncogene21 (2002) 7435-7451.
26. D.G. Yanbaeva, M.A. Dentener, E.C. Creutzberg, G. Wesseling, E.F. Wouters, Systemic effects of smoking, Chest 131 (2007) 1557-1566.
27. W.B. Kannel, T. Gordon, P.A. Wolf, et al., Hemoglobin and the risk of cerebralinfarction: the Framingham study, Stroke 3 (1972) 409-420.
28. K.V. Watson, N. Key, Vascular complications of essential thrombocythaemia:a link to cardiovascular risk factors, Br. J. Haematol. 83 (2) (1993) 198-203.
29. M.L. Randi, F. Fabris, G. Cella, C. Rossi, A. Girolami, Cerebral vascularaccidents in young patients with essential thrombocythemia: relation withother known cardiovascular risk factors, Angiology 49 (6) (1998) 477-481.
30. R. Jantunen, E. Juvonen, E. Ikkala, K. Oksanen, P. Anttila, T. Ruutu, Thepredictive value of vascular risk factors and gender for the development ofthrombotic complications in essential thrombocythemia, Ann. Hematol. 80 (2) (2001) 74-78.
31. R. Marchioli, G. Finazzi, G. Specchia, et al., Cardiovascular events andintensity of treatment in polycythemia vera, N. Engl. J. Med. 368 (2013) 22-33.
32. R. Marchioli, G. Finazzi, R. Landolfi, et al., Vascular and neoplastic risk in alarge cohort of patients with polycythemia vera, J. Clin. Oncol. 23 (2005) 2224-2232.
33. R. Landolfi, R. Marchioli, J. Kutti, et al., Efficacy and safety of low-dose aspirinin polycythemia vera, N. Engl. J. Med. 350 (2004) 114-124.
34. C.N. Harrison, P.J. Campbell, G. Buck, et al., United Kingdom medicalresearch council primary thrombocythemia 1 study. Hydroxyurea comparedwith anagrelide in high-risk essential thrombocythemia, N. Engl. J. Med. 353 (1) (2005) 33-45.
35. R. Landolfi, L. Di Gennaro, T. Barbui, et al., European collaboration onlow-dose aspirin in polycythemia vera (ECLAP). Leukocytosis as a majorthrombotic risk factor in patients with polycythemia vera, Blood 109 (6) (2007) 2446-2452.
36. B.L. Stein, A. Rademaker, J.L. Spivak, A.R. Moliterno, Gender and vascularcomplications in the JAK2 V617F-positive myeloproliferative neoplasms, Thrombosis (2011) 874146.
37. T. Barbui, G. Barosi, G. Birgegard, et al., European LeukemiaNet.Philadelphia-negative classical myeloproliferative neoplasms: criticalconcepts and management recommendations from European LeukemiaNet, J. Clin. Oncol. 29 (6) (2011) 761-770.
38. A. Tefferi, T. Barbui, Polycythemia vera and essential thrombocythemia:2015 update on diagnosis, risk-stratification and management, Am. J.Hematol. 90 (2) (2015) 162-173.
39. S. Fircanis, P. Merriam, N. Khan, J.J. Castillo, The relation between cigarettesmoking and risk of acute myeloid leukemia: an updated meta-analysis ofepidemiological studies, Am. J. Hematol. 89 (8) (2014) E125-E132.
40. H. Tong, C. Hu, X. Yin, M. Yu, J. Yang, J.A. Jin, Meta-analysis of therelationship between cigarette smoking and incidence of myelodysplasticsyndromes, PLoS One 8 (6) (2013 21) e67537.
41. C. Nielsen, H.S. Birgens, B.G. Nordestgaard, S.E. Bojesen, Diagnostic value ofJAK2 V617F somatic mutation for myeloproliferative cancer in 49 488individuals from the general population, Br. J. Haematol. 160 (1) (2013) 70-79.
42. I. Weinberg, A. Borohovitz, S. Krichevsky, R. Perlman, A. Ben-Yehuda, D. Ben-Yehuda, Janus kinase V617F mutation in cigarette smokers, Am. J.Hematol. 87 (1) (2012) 5-8.
43. M.E. Kroll, F. Murphy, K. Pirie, et al., Alcohol drinking, tobacco smoking andsubtypes of haematological malignancy in the UK Million Women Study, Br.J. Cancer 107 (2012) 879-887.
44. A.D. Leal, C.A. Thompson, A.H. Wang, et al., Anthropometric, medical historyand lifestyle risk factors for myeloproliferative neoplasms in the Iowawomen's health study cohort, Int. J. Cancer 134 (7) (2014) 1741-1750.
45. P. Pasqualetti, V. Festuccia, P. Acitelli, A. Collacciani, A. Giusti, R. Casale, Tobacco smoking and risk of haematological malignancies in adults: acase-control study, Br. J. Haematol. 97 (3) (1997) 659-662.
46. D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (1) (2000) 57-70.
47. E. Pikarsky, R.M. Porat, I. Stein, et al., NF-kappaB functions as a tumourpromoter in inflammation associated cancer, Nature 431 (7007) (2004) 461-466.
48. M. Karin, F.R. Greten, NF-kappaB linking inflammation and immunity tocancer development and progression, Nat. Rev. Immunol. 5 (10) (2005) 749-759.
49. A. Mantovani, C. Garlanda, P. Allavena, Molecular pathways and targets incancer-related inflammation, Ann. Med. 42 (3) (2010) 161-170.
50. M.J. Pittet, F.K. Swirski, Monocytes link atherosclerosis and cancer, Eur. J.Immunol. 41 (9) (2011) 2519-2522.
51. E. Komura, C. Tonetti, V. Penard-Lacronique, et al., Role for the nuclear factorkappaB pathway in transforming growth factor-beta1 production inidiopathic myelofibrosis: possible relationship with FK506 binding protein51 overexpression, Cancer Res. 65 (8) (2005) 3281-3289.
52. Y. Zhang, T. Pan, X. Zhong, C. Cheng, Nicotine upregulates microRNA-21 andpromotes TGF-β-dependent epithelial-mesenchymal transition ofesophageal cancer cells, Tumour Biol. 35 (7) (2014) 7063-7072.
53. H. Frederiksen, D.K. Farkas, C.F. Christiansen, H.C. Hasselbalch, H.T. Sørensen, Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danishpopulation-based cohort study, Blood 118 (25) (2011) 6515-6520.
54. H.C. Hasselbalch, The platelet-cancer loop in myeloproliferative cancer. Isthrombocythemia an enhancer of invasiveness and metastasis in essentialthrombocythemia, polycythemia vera and myelofibrosis? Leuk. Res. 38 (10) (2014) 1230-1236.
55. L. Yang, Y. Pang, H.L. Moses, TGF-beta and immune cells: an importantregulatory axis in the tumor microenvironment and progression, TrendsImmunol. 31 (6) (2010) 220-227.
56. G. Tagariello, R. Di Gaetano, R. Sartori, et al., The JAK2 (V617F) tyrosinekinase mutation in blood donors with upper-limit haematocrit levels, BloodTransfus. 7 (2009) 111-116.
57. S. Preston-Martin, M.C. Pike, R.K. Ross, P.A. Jones, B.E. Henderson, Increasedcell division as a cause of human cancer, Cancer Res. 50 (1990) 7415-7421.
58. H.C. Hasselbalch, Perspectives on the impact of JAK-inhibitor therapy uponinflammation-mediated comorbidities in myelofibrosis and relatedneoplasms, Expert. Rev. Hematol. 7 (2) (2014) 203-216.
59. S. Hermouet, A. Godard, D. Pineau, et al., Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera, Cytokine 20 (4) (2002) 178-183.
60. S. Emadi, D. Clay, C. Desterke, et al., IL-8 and its CXCR1 and CXCR2 receptorsparticipate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis, Blood 105 (2) (2005) 464-473.
61. A. Tefferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho, A. Pardanani, Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels areindependently prognostic in primary myelofibrosis: a comprehensivecytokine profiling study, J. Clin. Oncol. 29 (10) (2011) 1356-1363.
62. R. Vaidya, N. Gangat, T. Jimma, et al., Plasma cytokines in polycythemia vera:phenotypic correlates, prognostic relevance, and comparison withmyelofibrosis, Am. J. Hematol. 87 (11) (2012) 1003-1005.
63. J. Wehrle, T.S. Seeger, S. Schwemmers, D. Pfeifer, A. Bulashevska, H.L. Pahl, Transcription factor nuclear factor erythroid-2 mediates expression of thecytokine interleukin 8, a known predictor of inferior outcome in patientswith myeloproliferative neoplasms, Haematologica 98 (7) (2013) 1073-1080.
64. K. Kaufmann, A. Gründer, T. Hadlich, et al., A novel murine model ofmyeloproliferative disorders generated by overexpression of thetranscription factor NF-E2, J. Exp. Med. 209 (1) (2012) 35-50.
65. K. Kapralova, L. Lanikova, F. Lorenzo, J. Song, M. Horvathova, V. Divoky, J.T. Prchal, RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seenin polycythemic disorders with augmented HIF signaling, Blood 123 (3) (2014) 391-394.
66. H.C. Hasselbalch, A role of NF-E2 in chronic inflammation and clonalevolution in essential thrombocythemia, polycythemia vera andmyelofibrosis? Leuk. Res. 38 (2) (2014) 263-266.
67. Q. Zhang, X. Tang, Z.F. Zhang, R. Velikina, S. Shi, A.D. Le, Nicotine induceshypoxia-inducible factor-1alpha expression in human lung cancer cells vianicotinic acetylcholine receptor-mediated signaling pathways, Clin. CancerRes. 15;13 (16) (2007) 4686-4694.
68. S.N. Greer, J.L. Metcalf, Y. Wang, M. Ohh, The updated biology ofhypoxia-inducible factor, EMBO J. 31 (11) (2012) 2448-2460.
69. L. Zhang, C. Steinmaus, D.A. Eastmond, X.K. Xin, M.T. Smith, Formaldehydeexposure and leukemia: a new meta-analysis and potential mechanisms, Mutat. Res. 681 (2009) 150-168.
70. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. AReview of Human Carcinogens: Chemical Agents and Related Occupations.WHO International Agency for Research on Cancer 2012; 100F:401-435.
71. NTP. (National Toxicology Program). Report on Carcinogens, TwelfthEdition. Research Triangle Park. 2012; 195-205.
72. L.R. Rhomberg, L.A. Bailey, J.E. Goodman, A.K. Hamade, D. Mayfield, Isexposure to formaldehyde in air causally associated with leukemia?-Ahypothesis-based weight-of-evidence analysis, Crit. Rev. Toxicol. 41 (2011) 555-621.
73. L. Zhang, X. Tang, N. Rothman, R. Vermeulen, Z. Ji, et al., Occupationalexposure to formaldehyde, hematotoxicity, and leukemia-specificchromosome changes in cultured myeloid progenitor cells, CancerEpidemiol. Biomarkers Prev. 19 (2010) 80-88.
74. Y. Zhang, X. Liu, C. McHale, R. Li, L. Zhang, Y. Wu, X. Ye, X. Yang, S. Ding, Bonemarrow injury induced via oxidative stress in mice by inhalation exposureto formaldehyde, PLoS One 11;8 (9) (2013) e74974.
75. T. Yahata, T. Takanashi, Y. Muguruma, A.A. Ibrahim, H. Matsuzawa, et al., Accumulation of oxidative DNA damage restricts the self-renewal capacityof human hematopoietic stem cells, Blood 118 (2011) 2941-2950.
76. V. Skov, T.S. Larsen, M. Thomassen, et al., Whole blood transcriptionalprofiling of interferon inducible genes identifies highly upregulated IFI27 inprimary myelofibrosis, Eur. J. Haematol. 87 (1) (2011) 54-60.
77. V. Skov, M. Thomassen, C.H. Riley, et al., Gene expression profiling withprincipal component analysis depicts the biological continuum fromessential thrombocythemia over polycythemia vera to myelofibrosis, Exp.Hematol. 40 (9) (2012) 771-780.
78. V. Skov, T.S. Larsen, M. Thomassen, et al., Molecular profiling of peripheralblood cells from patients with polycythemia vera and related neoplasms:identification of deregulated genes of significance for inflammation andimmune surveillance, Leuk. Res. 36 (11) (2012) 1387-1392.
79. H.C. Hasselbalch, M. Thomassen, C. Hasselbalch Riley, et al., Whole bloodtranscriptional profiling reveals deregulation of oxidative and antioxidativedefence genes in myelofibrosis and related neoplasms. Potentialimplications of downregulation of Nrf2 for genomic instability and diseaseprogression, PLoS One 9 (11) (2014) e112786.
80. S. Hermouet, M. Vilaine, The JAK2 46/1 haplotype: a marker of inappropriatemyelomonocytic response to cytokine stimulation, leading to increased riskof inflammation, myeloid neoplasm, and impaired defense againstinfection? Haematologica 96 (11) (2011) 1575-1579.
81. T. Barbui, G. Finazzi, A. Falanga, Myeloproliferative neoplasms andthrombosis, Blood 122 (13) (2013) 2176-2184.
82. S.A. Harding, J. Sarma, D.H. Josephs, et al., Upregulation of the CD40/CD40ligand dyad and platelet-monocyte aggregation in cigarette smokers, Circulation 109 (2004) 1926-1929.
83. R. Gupta, S. Perumandla, Y. Patsiornik, S. Niranjan, A. Ohri, Incidence ofpulmonary hypertension in patients with chronic myeloproliferativedisorders, J. Natl. Med. Assoc. 98 (11) (2006) 1779-1782.
84. D. Zucker-Franklin, C.S. Philipp, Platelet production in the pulmonarycapillary bed: new ultrastructural evidence for an old concept, Am. J. Pathol.157 (2000) 69-74.
85. N. Tinggaard Pedersen, B. Laursen, Megakaryocytes in cubital venous bloodin patients with chronic myeloproliferative diseases, Scand. J. Haematol. 30 (1) (1983) 50-58.
86. H.C. Hasselbalch, V. Skov, L. Stauffer, T. arsen, et al., Transcriptional profilingof whole blood identifies a unique 5-gene signature for myelofibrosis andimminent myelofibrosis transformation, PLoS One 9 (1) (2014) e85567.
87. A. Tabarroki, D.J. Lindner, V. Visconte, et al., Ruxolitinib leads toimprovement of pulmonary hypertension in patients with myelofibrosis, Leukemia 28 (7) (2014) 1486-1493.
88. M. Suzuki, T. Betsuyaku, Y. Ito, et al., Down-regulated NF-E2-related factor 2in pulmonary macrophages of aged smokers and patients with chronicobstructive pulmonary disease, Am. J. Respir. Cell Mol. Biol. 39 (6) (2008) 673-682.
89. A. Muendlein, K. Gasser, E. Kinz, et al., Evaluation of the prevalence andprospective clinical impact of the JAK2 V617F mutation in coronary patients, Am. J. Hematol. 89 (3) (2014) 295-301.
90. A. Muendlein, E. Kinz, K. Gasser, et al., Occurrence of the JAK2 V617Fmutation in patients with peripheral arterial disease, Am. J. Hematol. 90 (1) (2015) E17-21.
91. S.Y. Kristinsson, O. Landgren, J. Samuelsson, M. Bjorkholm, L.R. Goldin, Autoimmunity and the risk of myeloproliferative neoplasms, Haematologica95 (7) (2010) 1216-1220.
92. L.R. Ferguson, D.Y. Han, A.G. Fraser, et al., Genetic factors in chronicinflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealandpopulation, Mutat. Res. 690 (1-2) (2010) 108-115.
93. J.C. Barrett, S. Hansoul, D.L. Nicolae, et al., Genome-wide association definesmore than 30 distinct susceptibility loci for Crohn's disease, Nat. Genet. 40 (8) (2008) 955-962.
94. A. Pardanani, B.L. Fridley, T.L. Lasho, et al., Host genetic variation contributesto phenotypic diversity in myeloproliferative disorders, Blood 111 (2008) 2785-2789.
95. K. Magnussen, H.C. Hasselbalch, H. Ullum, O.W. Bjerrum, Characterization ofblood donors with high haemoglobin concentration, Vox Sang. 104 (2) (2013) 110-114.
96. K. Larsson, D. Mellström, E. Nordborg, A. Odén, E. Nordborg, Earlymenopause, low body mass index, and smoking are independent risk factorsfor developing giant cell arteritis, Ann. Rheum. Dis. 65 (4) (2006) 529-532.
97. A. Ponder, M.D. Long, A clinical review of recent findings in the epidemiologyof inflammatory bowel disease, Clin. Epidemiol. 5 (2013) 237-247.
98. D. Di Bona, M. Cippitelli, C. Fionda, et al., Oxidative stress inhibitsIFN-alpha-induced antiviral gene expression by blocking the JAK-STATpathway, J. Hepatol. 45 (2) (2006) 271-279.
99. D.C. Rockey, P.D. Bell, J.A. Hill, Fibrosis-a common pathway to organ injuryand failure, N. Engl. J. Med. 372 (12) (2015) 1138-1149.
100. R. Ross, Atherosclerosis-an inflammatory disease, N. Engl. J. Med. 340 (1999) 115-126.